

ASX/ Media Release  
31 October 2017

## Quarterly Activities & Cash Flow Report Quarter ended 30 September 2017

*Investor Call to discuss Quarterly Results and Outlook at 9.00am AEDT, 8<sup>th</sup> November 2017*

**Sydney, Australia, 31 October 2017:** OncoSil Medical Limited (ASX: OSL) (**OncoSil Medical** or the **Company**) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, today released its Appendix 4C – Quarterly Cash flow report for the Quarter ended 30 September 2017 (the **Quarter**). All financial results are in Australian dollars and are unaudited.

### Key Points

- The Company presented positive early study results at the European Association of Nuclear Medicine (EANM) Congress in Vienna
- 28 subjects now enrolled into currently study (up from 13 subjects at the end of FY4Q 17)
- Cash balance as at 30 September of \$8.5m, with cash inflow from operations for the Quarter of \$0.5m net of R&D tax refund of \$2.9m

OncoSil Chief Executive Officer, Daniel Kenny commented:

*“During the Quarter, we continued to progress recruitment for the study programme, and I am pleased that, with 28 subjects currently enrolled, we have exceeded the required 20 patient provision of supplemental data to BSI for CE Mark approval.*

*“I am greatly encouraged by our study results so far, showing early and substantial tumour volume reduction at 4 weeks post implant and to date, 100% disease control rate at Week 8, as well as confirming the safety of the device and validating the procedural implantation method.*

*“I look forward to the Company’s progression during the next quarter, as we near closer to providing the BSI with the required supplemental data, and receiving CE Mark certification soon after.”*

### Global Pancreatic Clinical Study Programme

OncoSil continues to progress recruitment for the study, with 28 patients now enrolled in the study and 14 patients implanted with the OncoSil™ device.

The Company will continue to recruit subjects beyond the initial 20 subject target to gather additional valuable clinical experience and to account for subject loss due to factors such as withdrawal on clinical grounds prior to implantation or protocol ineligibility.

## Early Study Results

OncoSil's Chief Medical Officer, Ashish Soman, provided an overview of early study results at the EANM Congress in Vienna on 21 October; these results were shared with the market shortly thereafter.

The data presented was an analysis of the 14 subjects implanted with the OncoSil™ device, used with concurrent chemotherapy, who completed radiological evaluation in the 8, 16, and 24-week study follow-up periods. This positive early study data is consistent with previously completed studies that validated the safety, efficacy and delivery of the OncoSil™ device.

### Key highlights of the results to date include:

- 100% Disease Control Rate (DCR) at Week 8 (meaning all patients experienced stable disease or better).
- Early and substantial tumour volume reductions in participants at Week 4; up to 73% volumetric reduction and a median volumetric reduction of 34.5%
- No Serious Adverse Events (SAE) attributed to the device or implant procedure, no evidence of radiation toxicities, and no other safety concerns identified to date
- Device delivery via Endoscopic Ultrasound (EUS) considered easy and uncomplicated

## Corporate and Financial

During the Quarter, the Company received an R&D tax incentive cash refund of \$2.9m. The cash outflow from operations (excluding R&D tax incentive refund) was \$2.4m, resulting in a cash balance as at 30 September 2017 of \$8.5m.

The Company hosted its Annual General Meeting on 25 October 2017.

## Investor Conference Call

The Company will hold a conference call at 9:00am AEDT on 8<sup>th</sup> November 2017 to discuss the Company's financial results for the Quarter and the business outlook. The Company's Chief Executive Officer and Managing Director, Daniel Kenny, will host the call.

**To access the call please use the following details: Conference ID: 554741**

<b>Australian Toll Free:</b>	<b>1800 908 299</b>
<b>Australia Local</b> (if dialling from international location):	<b>+61 2 9007 8048</b>
<b>New Zealand Toll Free:</b>	<b>0800 452 795</b>
<b>Hong Kong Toll Free:</b>	<b>800 968 273</b>
<b>Singapore Toll Free:</b>	<b>800 101 2702</b>
<b>China Toll Free:</b>	<b>1080 0140 1776</b>
<b>United Kingdom Toll Free:</b>	<b>0800 051 1453</b>
<b>United States/Canada Toll Free:</b>	<b>1855 624 0077</b>

- ENDS -

Company	Media
<b>Mr Daniel Kenny</b> CEO & Managing Director E: <a href="mailto:daniel.kenny@oncosil.com.au">daniel.kenny@oncosil.com.au</a> T: +61 2 9223 3344	<b>Ben Walsh</b> WE Buchan E: <a href="mailto:bwalsh@buchanwe.com.au">bwalsh@buchanwe.com.au</a> M: 0411 520 012

## About OncoSil

OncoSil™ is a clinical-stage medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical trials with encouraging results on tolerability, safety and efficacy. A CE Mark application to commercially sell OncoSil™ in the European Union (EU) is under review with commercial launch planned for 2H2016, subject to approval.

The U.S Food and Drug Administration granted an Investigational Device Exemption (IDE) in July 2016 with approval to conduct a clinical study of the OncoSil™ device. The aim of the study will be to collect safety and effectiveness data required to support a Premarket Approval (PMA) application.

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6<sup>th</sup> most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to \$1.4b by 2019.

## Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

**ONCOSIL MEDICAL LIMITED**

**ABN**

89 113 824 141

**Quarter ended ("current quarter")**

30 September 2017

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>			
1.1 Receipts from customers	-	-	-
1.2 Payments for			
(a) research and development	(952)	(952)	(952)
(b) product manufacturing and operating costs	-	-	-
(c) advertising and marketing	-	-	-
(d) leased assets	-	-	-
(e) staff costs	(1,228)	(1,228)	(1,228)
(f) administration and corporate costs	(231)	(231)	(231)
1.3 Dividends received (see note 3)	-	-	-
1.4 Interest received	37	37	37
1.5 Interest and other costs of finance paid	-	-	-
1.6 Income taxes paid	-	-	-
1.7 Government grants and tax incentives	2,885	2,885	2,885
1.8 Other (provide details if material)	-	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>511</b>	<b>511</b>	<b>511</b>
<b>2. Cash flows from investing activities</b>			
2.1 Payments to acquire:			
(a) property, plant and equipment	-	-	-
(b) businesses (see item 10)	-	-	-
(c) investments	-	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:	-	-
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

<b>3.</b>	<b>Cash flows from financing activities</b>	-	-
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>-</b>	<b>-</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of quarter/year to date	8,001	8,001
4.2	Net cash from / (used in) operating activities (item 1.9 above)	511	511
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	1	1
4.6	<b>Cash and cash equivalents at end of quarter</b>	<b>8,513</b>	<b>8,513</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	8,513	8,513
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>8,513</b>	<b>8,513</b>

6.	Payments to directors of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to these parties included in item 1.2	60
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

7.	Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1	Aggregate amount of payments to these parties included in item 1.2	
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

**8. Financing facilities available**

*Add notes as necessary for an understanding of the position*

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000

8.1 Loan facilities

8.2 Credit standby arrangements

8.3 Other (please specify)

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

--

**9. Estimated cash outflows for next quarter**

**\$A'000**

9.1 Research and development

1,500

9.2 Product manufacturing and operating costs

-

9.3 Advertising and marketing

-

9.4 Leased assets

-

9.5 Staff costs

1,400

9.6 Administration and corporate costs

250

9.7 Other (Annual License Fee payment)

130

**9.8 Total estimated cash outflows**

**3,280**

**10. Acquisitions and disposals of business entities  
(items 2.1(b) and 2.2(b) above)**

**Acquisitions**

**Disposals**

10.1 Name of entity

10.2 Place of incorporation or registration

10.3 Consideration for acquisition or disposal

10.4 Total net assets

10.5 Nature of business

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:   
(Company secretary)

Date: 31 October 2017

Print name: Tom Milicevic

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.